Búsqueda | BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas

1.

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

Joerger, M; Hess, D; Delmonte, A; Gallerani, E; Fasolo, A; Gianni, L; Cresta, S; Barbieri, P; Pace, S; Sessa, C.

Br J Clin Pharmacol ; 80(1): 128-38, 2015 Jul.

Artículo en Inglés | MEDLINE | ID: mdl-25580946

2.

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

Gianni, L; Munzone, E; Capri, G; Villani, F; Spreafico, C; Tarenzi, E; Fulfaro, F; Caraceni, A; Martini, C; Laffranchi, A.

J Natl Cancer Inst ; 87(15): 1169-75, 1995 Aug 02.

Artículo en Inglés | MEDLINE | ID: mdl-7674322

3.

Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium.

Minotti, G; Saponiero, A; Licata, S; Menna, P; Calafiore, A M; Teodori, G; Gianni, L.

Clin Cancer Res ; 7(6): 1511-5, 2001 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-11410484

4.

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

Sparreboom, A; Verweij, J; van der Burg, M E; Loos, W J; Brouwer, E; Viganò, L; Locatelli, A; de Vos, A I; Nooter, K; Stoter, G; Gianni, L.

Clin Cancer Res ; 4(8): 1937-42, 1998 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9717822

5.

Future directions of paclitaxel-based therapy of breast cancer.

Gianni, L.

Semin Oncol ; 24(5 Suppl 17): S17-91-S17-96, 1997 Oct.

Artículo en Inglés | MEDLINE | ID: mdl-9374103

6.

The role of taxanes in the treatment of breast cancer.

Capri, G; Tarenzi, E; Fulfaro, F; Gianni, L.

Semin Oncol ; 23(1 Suppl 2): 68-75, 1996 Feb.

Artículo en Inglés | MEDLINE | ID: mdl-8614849

7.

Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.

Gianni, L.

Oncology (Williston Park) ; 12(1 Suppl 1): 13-5, 1998 Jan.

Artículo en Inglés | MEDLINE | ID: mdl-9516596

8.

Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients.

Tononi, A; Panzini, I; Oliverio, G; Pasquini, E; Gianni, L; Nicolini, M; Ravaioli, A.

J Chemother ; 9(4): 304-8, 1997 Aug.

Artículo en Inglés | MEDLINE | ID: mdl-9269613

9.

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.

Sessa, C; Cresta, S; Cerny, T; Baselga, J; Rota Caremoli, E; Malossi, A; Hess, D; Trigo, J; Zucchetti, M; D'Incalci, M; Zaniboni, A; Capri, G; Gatti, B; Carminati, P; Zanna, C; Marsoni, S; Gianni, L.

Ann Oncol ; 18(3): 561-8, 2007 Mar.

Artículo en Inglés | MEDLINE | ID: mdl-17150998

10.

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.

van Zuylen, L; Gianni, L; Verweij, J; Mross, K; Brouwer, E; Loos, W J; Sparreboom, A.

Anticancer Drugs ; 11(5): 331-7, 2000 Jun.

Artículo en Inglés | MEDLINE | ID: mdl-10912949

11.

Theoretical and practical aspects of paclitaxel scheduling.

Gianni, L.

Ann Oncol ; 6(9): 861-3, 1995 Nov.

Artículo en Inglés | MEDLINE | ID: mdl-8624286

12.

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex.

Myers, C E; Gianni, L; Simone, C B; Klecker, R; Greene, R.

Biochemistry ; 21(8): 1707-12, 1982 Apr 13.

Artículo en Inglés | MEDLINE | ID: mdl-6805506

13.

Is acute dyspnoea a rare side effect of vinorelbine?

Tassinari, D; Sartori, S; Gianni, L; Pasguini, E; Ravaioli, A.

Ann Oncol ; 8(5): 503-4, 1997 May.

Artículo en Inglés | MEDLINE | ID: mdl-9233534

BVS Medicinas Tradicionales, Complementarias, e Integrativas en las Américas - MTCI

Configurar filtros

Su selección (0)

Formato de exportación:

Exportar:

Integrative population pharmacokinetic and pharmacodynamic dose finding approach of the new camptothecin compound namitecan (ST1968).

Paclitaxel in metastatic breast cancer: a trial of two doses by a 3-hour infusion in patients with disease recurrence after prior therapy with anthracyclines.

Paclitaxel and docetaxel enhance the metabolism of doxorubicin to toxic species in human myocardium.

Disposition of Cremophor EL in humans limits the potential for modulation of the multidrug resistance phenotype in vivo.

Future directions of paclitaxel-based therapy of breast cancer.

The role of taxanes in the treatment of breast cancer.

Paclitaxel plus doxorubicin in metastatic breast Ca: the Milan experience.

Vinorelbine chemotherapy in non small cell lung cancer: experience in elderly patients.

Concerted escalation of dose and dosing duration in a phase I study of the oral camptothecin gimatecan (ST1481) in patients with advanced solid tumors.

Inter-relationships of paclitaxel disposition, infusion duration and cremophor EL kinetics in cancer patients.

Theoretical and practical aspects of paclitaxel scheduling.

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex.

Is acute dyspnoea a rare side effect of vinorelbine?